Targeting Cav2.2 channels for pain management: challenges, innovations, and future perspectives.

N-type voltage-gated calcium channels (Cav2.2) are validated targets for chronic pain management. Although ziconotide is clinically effective, its use is hampered by a narrow therapeutic window and severe side effects. This review examines the subunit structure of Cav2.2 and its fundamental role in nociceptive signaling. We focus on emerging therapeutic strategies developed in recent years, including the optimization of direct blockade, the inhibition of channel trafficking, the modulation of signaling pathways, and targeted channel depletion. These advancements provide a deeper understanding of calcium channel regulation and identify promising targets for safer, more effective, and precision-based pain management.